Novartis' Anti-Seizure Drug New Target Of PL Suit

Law360, New York (December 5, 2007, 12:00 AM EST) -- Already besieged by hundreds of product liability suits surrounding its contentious bone density drugs, Novartis Pharmaceuticals Corp. is now facing a fresh assault over anti-seizure medication Trileptal.

The lawsuit, believed to be one of the first of its kind, was removed to a Florida district court Monday. It claims Trileptal has life-threatening side effects that Novartis deliberately concealed from consumers.

Plaintiff Lori Feldman initially brought the suit in a Florida state court, alleging she suffered a serious adverse reaction and was diagnosed with the debilitating Stevens-Johnson...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.